Spartan Bioscience's CE-Marked CYP2C19 Test Will Also Be Submitted to the FDA

Spartan Bioscience has gained a CE IVD Mark for its Spartan RX CYP2C19 point-of-care test to guide antiplatelet treatment. Meanwhile, the firm is planning a US regulatory filing in 2011.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.